Taken together, the experiments shown in Figure 4 suggest that, compared to DOXO-treated cells, sGC activator vericiguat exerts strong anti-inflammatory effects through the reduction of two key players of cardiomyopathies and sarcopenia. The gene discussed is SGCB; the disease is sarcopenia.